A Phase 1 Study of ¹³¹I-CLR1404 in Patients with Relapsed or Refractory Advanced Solid Tumors: Dosimetry, Biodistribution, Pharmacokinetics, and Safety

• Joseph J. Grudzinski ,

  * E-mail: grudzinski@wisc.edu

  Affiliations Cellectar Biosciences, Inc., Madison, WI, United States of America, Department of Medical Physics, University of Wisconsin School of Medicine and Public Health, Madison, WI, United States of America

  ⨯
• Benjamin Titz,

  Affiliations Cellectar Biosciences, Inc., Madison, WI, United States of America, Department of Medical Physics, University of Wisconsin School of Medicine and Public Health, Madison, WI, United States of America

  ⨯
• Kevin Kozak,

  Affiliation Cellectar Biosciences, Inc., Madison, WI, United States of America

  ⨯
• William Clarke,

  Affiliation Cellectar Biosciences, Inc., Madison, WI, United States of America

  ⨯
• Ernest Allen,

  Affiliation Cellectar Biosciences, Inc., Madison, WI, United States of America

  ⨯
• LisaAnn Trembath,

  Affiliation Cellectar Biosciences, Inc., Madison, WI, United States of America

  ⨯
• Michael Stabin,

  Affiliation Department of Radiology and Radiological Sciences, Vanderbilt University, Nashville, TN, United States of America

  ⨯
• John Marshall,

  Affiliation Department of Medicine and Lombardi Comprehensive Cancer Center, Medstar Georgetown University Hospital, Washington, DC, United States of America

  ⨯
• Steve Y. Cho,

  Affiliation Department of Radiology, Johns Hopkins Hospital, Baltimore, MD, United States of America

  ⨯
• Terence Z. Wong,

  Affiliation Department of Radiology, Duke University Medical Center, Durham, NC, United States of America

  ⨯
• Joanne Mortimer,

  Affiliation Department of Medical Oncology and Therapeutics Research, City of Hope, Duarte, CA, United States of America

  ⨯
• Jamey P. Weichert

  Affiliations Cellectar Biosciences, Inc., Madison, WI, United States of America, Department of Radiology, University of Wisconsin, Madison, WI, United States of America

  ⨯